Tibsovo is the first medicine to treat cancer of the spinal cord

The US Food and Drug Administration (FDA) has approved a new drug to treat adult patients with acute myeloid leukemia, or leukemia, with a specific genetic mutation.

Cancer therapy includes drugs or substances that inhibit its growth and spread by interfering with some of the molecules involved in the growth and spread of tumors.

The efficacy and safety of the new drug was tested after an experiment with 174 adult patients with the disease, some of whom had a specific genetic mutation.

Of the 110 patients who initially requested blood transfusions or platelets, 37% remained at least 56 days without transfusion after treatment with the new drug.

The most common side effects of the drug include increased white blood cells, joint pain, diarrhea, shortness of breath, swollen arms or legs, and nausea.

The patient may also experience pain or ulcers in the mouth or throat, irregular heartbeat, rash, fever, cough, and constipation.

Depending on the body, acute myeloid leukemia is formed in the bone marrow, and leads to an increase in the number of white blood cells in the blood.

According to estimates by the US National Cancer Institute, he will diagnose approximately 21,000 cases of acute myeloid leukemia this year in the United States.

The US Food and Drug Administration is an agency of the US Department of Health and Human Rights charged with protecting and promoting public health through regulation and oversight of food, pharmaceutical and biopharmaceutical safety . Vision News: Tibsovo is the first drug to treat leukemia.You can see the original source of information from the following link: Vision News and leave the site of the unit for its full responsibility for the content of the news, but it's the responsibility of the original news editor